Nav: Home

Roadmap to get new cancer scans into clinic

October 11, 2016

A team of international scientists has outlined key recommendations for a global standard for scanning biomarkers in cancer - to bridge the gap between research and the clinic, according to a new paper published in Nature Reviews Clinical Oncology* today (Tuesday).

Scans have transformed the way that doctors treat cancer patients and are integral to most key treatment decisions - including CT, MRI and PET scans.

But they are more than just a photograph or snap shot in time. They are a non-invasive way of getting a 3D perspective on cancer and provide dynamic information on diagnosis, staging, and decision-making during treatment - and are also used to target treatment accurately.

Many new types of scanning techniques are developed every year, including finding new biomarkers to measure what's going inside the body.

But not many end up reaching patients. This may be because the research has not yet shown them to be reliable or cost effective.

To get more tests from bench to bedside, 78 experts from Europe and North America, who specialise in imaging techniques, have identified the difficulties getting tests adopted in the clinic and set out 14 recommendations.

These include recommendations for grant submissions, for making sure results are reproducible across laboratories, for comparing scans with other tests such as liquid biopsy, and ensuring that techniques are cost effective.

For example, trials for antiangiogenics - drugs that "starve" tumours by disrupting blood vessels bringing oxygen and nutrients - have shown great promise. Advanced scanning can detect when these drugs are working in patients. But at the moment, methodologies vary greatly across hospitals and this stops these techniques being widely used in the clinic.

If all machines from different manufacturers are calibrated in the same way across different hospitals, larger clinical trials could be more easily set up to produce more powerful evidence to show if new scanning techniques are effective.

Dr James O'Connor, Cancer Research UK scientist and lead author at the University of Manchester, said: "Scans have helped advance the understanding of how cancer behaves. They have also transformed how we treat patients with cancer every day. They have shown great promise for monitoring the effects of new drugs and other treatments as they undergo development.

"If these recommendations raise the bar in imaging research, we can expect scans to play a much greater role in personalised medicine and to further improve the lives of patients with cancer having cutting edge therapies."

Jamie Meredith, Cancer Research UK's Head of Therapeutic Discovery Funding, said: "We want to make sure that the research we fund makes it to patients. An internationally agreed approach to accelerate the development and clinical use of imaging technology, could make us far more effective at diagnosing and tracking the disease.

"This is an excellent example of how the CRUK-EPSRC Cancer Imaging Centres are influencing best practice in the field."

Yan Liu, EORTC's Clinical Leader for the Medical and TRI Department said: "Academic research can play a critical role in ensuring fundamental research and technological innovation reach patients. This collaboration is a great example of how organisations can bring expertise together to identify and resolve issues in getting the imaging biomarkers introduced into clinical practice to make a bigger impact on people's lives."
For media enquiries contact Stephanie McClellan in the Cancer Research UK press office on 020 3469 5314 or, out of hours, on 07050 264 059.

Notes to editor:

* O'Connor et al. Imaging biomarker roadmap for cancer studies. Nature Reviews Clinical Oncology

CRUK-EPSRC Cancer Imaging Centres

EORTC (European Organisation for Research and Treatment of Cancer)

This review was conducted by EORTC and funded by Cancer Research UK, Engineering and Physical Sciences Research Council and supported by the Innovative Medicines Initiative Joint Undertaking ( under grant agreement number 115151 - QuIC-ConCePT..

About Cancer Research UK
  • Cancer Research UK is the world's leading cancer charity dedicated to saving lives through research.
  • Cancer Research UK's pioneering work into the prevention, diagnosis and treatment of cancer has helped save millions of lives.
  • Cancer Research UK receives no government funding for its life-saving research. Every step it makes towards beating cancer relies on every pound donated.
  • Cancer Research UK has been at the heart of the progress that has already seen survival in the UK double in the last forty years.
  • Today, 2 in 4 people survive their cancer for at least 10 years. Cancer Research UK's ambition is to accelerate progress so that by 2034, 3 in 4 people will survive their cancer for at least 10 years.
  • Cancer Research UK supports research into all aspects of cancer through the work of over 4,000 scientists, doctors and nurses.
  • Together with its partners and supporters, Cancer Research UK's vision is to bring forward the day when all cancers are cured.
For further information about Cancer Research UK's work or to find out how to support the charity, please call 0300 123 1022 or visit Follow us on Twitter and Facebook.

Cancer Research UK

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Changing The World
What does it take to change the world for the better? This hour, TED speakers explore ideas on activism—what motivates it, why it matters, and how each of us can make a difference. Guests include civil rights activist Ruby Sales, labor leader and civil rights activist Dolores Huerta, author Jeremy Heimans, "craftivist" Sarah Corbett, and designer and futurist Angela Oguntala.
Now Playing: Science for the People

#521 The Curious Life of Krill
Krill may be one of the most abundant forms of life on our planet... but it turns out we don't know that much about them. For a create that underpins a massive ocean ecosystem and lives in our oceans in massive numbers, they're surprisingly difficult to study. We sit down and shine some light on these underappreciated crustaceans with Stephen Nicol, Adjunct Professor at the University of Tasmania, Scientific Advisor to the Association of Responsible Krill Harvesting Companies, and author of the book "The Curious Life of Krill: A Conservation Story from the Bottom of the World".